Multicast capability in a virtual private LAN service (VPLS) is provided in a provider IP / MPLS infrastructure without headend replications by encapsulating a customer data packet to use an established multicast protocol, such as IP multicast. In one example, the customer data packet is encapsulated by an IP header having an IP multicast group address and an Ethernet header. In one implementation, a DNS type mechanism is provided to distribute the IP multicast addresses for VPLS use. Such IP multicast group address can be set aside from an administratively scoped address range. An efficient IP routing algorithm running on the provider's network provides an efficient distribution tree for routing IP-encapsulated customer packet for the VPLS.
The present invention relates to compounds that inhibit serineprotease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
The present invention relates to compounds of formula I: or a pharmaceutically acceptable salts thereof that inhibit serineprotease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
The invention described herein encompasses a methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group of polyphenols found in green tea, to a mammal in need of such therapy. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). The unique compositions of the invention contain various combinations of the catechins, alone or in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses the varying modes of administration of the therapeutic compounds, including a sustained release formulation which may be used as a therapeutic compound for the treatment of cancer or as a dietary supplement for the prevention of cancer.